TABLE OF CONTENTS
1 INTRODUCTION 22
1.1 OBJECTIVES OF THE STUDY 22
1.2 MARKET DEFINITION 22
1.3 OVERVIEW OF THE GLOBAL IMPLANTABLE PORTS MARKET 22
1.4 CURRENCY AND PRICING 23
1.5 LIMITATIONS 23
1.6 MARKETS COVERED 23
2 MARKET SEGMENTATION 25
2.1 MARKETS COVERED 25
2.2 GEOGRAPHICAL SCOPE 26
2.3 YEARS CONSIDERED FOR THE STUDY 27
2.4 DBMR TRIPOD DATA VALIDATION MODEL 28
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 31
2.6 MULTIVARIATE MODELLING 32
2.7 TYPE SEGMENT LIFELINE CURVE 32
2.8 MARKET END USERS COVERAGE GRID 33
2.9 DBMR MARKET POSITION GRID 34
2.10 VENDOR SHARE ANALYSIS 35
2.11 SECONDARY SOURCES 36
2.12 ASSUMPTIONS 36
3 EXECUTIVE SUMMARY 37
4 PREMIUM INSIGHTS 39
4.1 CONSUMER BUYING BEHAVIOUR 42
4.2 FACTORS AFFECTING BUYING DECISION 42
4.3 PRODUCT ADOPTION SCENARIO 42
4.4 REGULATION COVERAGE 43
4.5 BRAND ANALYSIS 45
4.6 RAW MATERIAL SOURCING ANALYSIS 46
4.7 IMPORT EXPORT SCENARIO 46
4.8 PORTER’S 5 FORCES 48
5 SUPPLY CHAIN ANALYSIS 49
5.1 LOGISTIC COSTS SCENARIO 49
5.2 IMPORTANCE OF LOGISTICS SERVICE PROVIDERS 49
6 MARKET OVERVIEW 51
6.1 DRIVERS 53
6.1.1 INCREASING PREVALENCE OF CHRONIC DISEASES 53
6.1.2 GROWING DEMAND FOR MINIMALLY INVASIVE PROCEDURES 53
6.1.3 INCREASING ONCOLOGY AND CHEMOTHERAPY PROCEDURES 54
6.1.4 IMPROVED DEVICE DESIGN AND FUNCTIONALITY 54
6.2 RESTRAINTS 55
6.2.1 RISK OF INFECTIONS AND MECHANICAL COMPLICATIONS 55
6.2.2 STRINGENT REGULATORY REQUIREMENTS FOR APPROVAL PROCESS 55
6.3 OPPORTUNITIES 56
6.3.1 RISING DEMAND FOR IMPLANTABLE PORT DEVICES DUE TO HIGH SUCCESS RATE 56
6.3.2 EXPANSION OF HOME-BASED HEALTHCARE 56
6.4 CHALLENGES 57
6.4.1 LACK OF SKILLED PROFESSIONALS OR EXPERTISE 57
6.4.2 PRODUCT RECALL OF IMPLANTABLE PORT DEVICES 57
7 GLOBAL IMPLANTABLE PORTS MARKET, BY TYPE 59
7.1 OVERVIEW 60
7.2 SINGLE LUMEN 63
7.3 DOUBLE LUMEN 63
7.4 POWER- INJECTABLE 64
8 GLOBAL IMPLANTABLE PORTS MARKET, BY MATERIAL 65
8.1 OVERVIEW 66
8.2 POLYURETHANE 69
8.3 SILICONE 69
8.4 TITANIUM 70
8.5 OTHERS 71
9 GLOBAL IMPLANTABLE PORTS MARKET, BY APPLICATION 72
9.1 OVERVIEW 73
9.2 CHEMOTHERAPY 76
9.3 BLOOD TRANSFUSION 76
9.4 ANTIBIOTICS 77
9.5 INTRAVENOUS INFUSION OF BLOOD PRODUCT 78
9.6 PAIN MANAGEMENT 78
9.7 OTHERS 79
10 GLOBAL IMPLANTABLE PORTS MARKET, BY END USERS 80
10.1 OVERVIEW 81
10.2 HOSPITALS 84
10.3 CLINICS 84
10.4 AMBULATORY SURGICAL CENTER 85
10.5 DIALYSIS CENTER 85
10.6 OTHERS 87
11 GLOBAL IMPLANTABLE PORTS MARKET, BY REGION 88
11.1 OVERVIEW 89
11.2 NORTH AMERICA 94
11.2.1 U.S. 100
11.2.2 CANADA 102
11.2.3 MEXICO 104
11.3 EUROPE 106
11.3.1 GERMANY 112
11.3.2 U.K. 114
11.3.3 FRANCE 116
11.3.4 ITALY 118
11.3.5 RUSSIA 120
11.3.6 SPAIN 122
11.3.7 NETHERLANDS 124
11.3.8 SWITZERLAND 126
11.3.9 BELGIUM 128
11.3.10 TURKEY 130
11.3.11 REST OF EUROPE 132
11.4 ASIA-PACIFIC 133
11.4.1 CHINA 139
11.4.2 JAPAN 141
11.4.3 INDIA 143
11.4.4 AUSTRALIA & NEW ZEALAND 145
11.4.5 SOUTH KOREA 147
11.4.6 INDONESIA 149
11.4.7 PHILIPPINES 151
11.4.8 THAILAND 153
11.4.9 MALAYSIA 155
11.4.10 SINGAPORE 157
11.4.11 REST OF ASIA-PACIFIC 159
11.5 SOUTH AMERICA 160
11.5.1 BRAZIL 166
11.5.2 ARGENTINA 168
11.5.3 REST OF SOUTH AMERICA 170
11.6 MIDDLE EAST & AFRICA 171
11.6.1 SAUDI ARABIA 177
11.6.2 SOUTH AFRICA 179
11.6.3 U.A.E 181
11.6.4 EGYPT 183
11.6.5 ISRAEL 185
11.6.6 REST OF MIDDLE EAST & AFRICA 187
12 GLOBAL IMPLANTABLE PORTS MARKET: COMPANY LANDSCAPE 188
12.1 COMPANY SHARE ANALYSIS: GLOBAL 188
12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 189
12.3 COMPANY SHARE ANALYSIS: EUROPE 190
12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 191
13 SWOT 192
14 GLOBAL IMPLANTABLE PORTS MARKET, COMPANY PROFILE 193
14.1 B.BRAUN SE 193
14.1.1 COMPANY SNAPSHOT 193
14.1.2 COMPANY SHARE ANALYSIS 193
14.1.3 PRODUCT PORTFOLIO 194
14.1.4 RECENT DEVELOPMENTS 194
14.2 ANGIODYNAMICS 195
14.2.1 COMPANY SNAPSHOT 195
14.2.2 REVENUE ANALYSIS 195
14.2.3 COMPANY SHARE ANALYSIS 196
14.2.4 PRODUCT PORTFOLIO 196
14.2.5 RECENT DEVELOPMENT 196
14.3 BD 197
14.3.1 COMPANY SNAPSHOT 197
14.3.2 REVENUE ANALYSIS 197
14.3.3 COMPANY SHARE ANALYSIS 198
14.3.4 PRODUCT PORTFOLIO 198
14.3.5 RECENT DEVELOPMENT 198
14.4 TELEFLEX INCORPORATED 199
14.4.1 COMPANY SNAPSHOT 199
14.4.2 REVENUE ANALYSIS 199
14.4.3 COMPANY SHARE ANALYSIS 200
14.4.4 PRODUCT PORTFOLIO 200
14.4.5 RECENT DEVELOPMENTS 200
14.5 VYGON 201
14.5.1 COMPANY SNAPSHOT 201
14.5.2 COMPANY SHARE ANALYSIS 201
14.5.3 PRODUCT PORTFOLIO 202
14.5.4 RECENT DEVELOPMENT 202
14.6 AMI GMBH 203
14.6.1 COMPANY SNAPSHOT 203
14.6.2 PRODUCT PORTFOLIO 203
14.6.3 RECENT DEVELOPMENT 203
14.7 DISTRICLASS MÉDICAL 204
14.7.1 COMPANY SNAPSHOT 204
14.7.2 PRODUCT PORTFOLIO 204
14.7.3 RECENT DEVELOPMENT 204
14.8 ICU MEDICAL, INC. 205
14.8.1 COMPANY SNAPSHOT 205
14.8.2 REVENUE ANALYSIS 205
14.8.3 PRODUCT PORTFOLIO 206
14.8.4 RECENT DEVELOPMENT 206
14.9 PAKUMEDMEDICAL PRODUCTS GMBH 207
14.9.1 COMPANY SNAPSHOT 207
14.9.2 PRODUCT PORTFOLIO 207
14.9.3 RECENT DEVELOPMENTS 207
15 QUESTIONNAIRE 208
16 RELATED REPORTS 211
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
